Intestinal Research

Review

IBD

Precision medicine in inflammatory bowel diseases: Ashwin N. Ananthakrishnan; Intest Res 2024;22(1):8-14. Published online November 9, 2023; DOI: https://doi.org/10.5217/ir.2023.00087

Inflammatory bowel diseases comprising Crohn’s disease and ulcerative colitis have emerged as global diseases. Multiple distinct therapeutic mechanisms have allowed us to increase our rates of achieving remission and reducing permanent disease-related morbidity. However, there is limited data to inform relative positioning of different therapies. This review will summarize existing literature on use of clinical decision models to inform relative efficacy of one therapeutic mechanism compared to the other given individual patient characteristics. It will also demonstrate the value of serologic, transcriptomic (from biopsies), and microbiome-based biomarkers in identifying which therapy is most likely to work for a given patient. We will review the existing gaps in the literature in this field and suggest a path forward for future studies to better inform patient care, incorporating the principles of precision medicine in the management of inflammatory bowel disease.

Citations

Citations to this article as recorded by

Prevalence, Clinical Characteristics, and Predictors of Difficult-to-Treat Inflammatory Bowel Disease in a Real-World Taiwanese Cohort
Shun-Wen Hsiao, Pei-Yuan Su, Chen-Ta Yang, Yang-Yuan Chen, Hsu-Heng Yen
Life.2026; 16(2): 197. CrossRef
Determination of correlation of clearance with clinical outcomes for inflammatory bowel disease
Diane R Mould, Maximillian Kutschera, Christian Primas, Sieglinde Reinisch, Gottfried Novacek, Cornelia Lichtenberger, Thierry Dervieux, Yunju Bae, Sun Hee Lee, Joon Ho Lee, Walter Reinisch
World Journal of Gastroenterology.2026;[Epub] CrossRef
In which patients with ulcerative colitis would filgotinib be effective?
Jihye Park
Intestinal Research.2025; 23(1): 1. CrossRef
Optimizing Infliximab Use in Real-World Inflammatory Bowel Disease: Insights from a Population Pharmacokinetic Model Integrating Intravenous and Subcutaneous Formulations
Sung Hoon Jung, Sang-Bum Kang
Gut and Liver.2025; 19(3): 299. CrossRef
Evolution of inflammatory bowel disease in Korea: a 60-year perspective on clinical and research development
Suk-Kyun Yang
Intestinal Research.2025; 23(3): 233. CrossRef
Assessing tuberculosis risk in Crohn’s disease patients receiving biologic therapies: real-world insights from Japan
Jung Won Lee, Yoo Min Han
Intestinal Research.2025; 23(3): 231. CrossRef
Oral–gut microbiome axis in a Korean cohort with inflammatory bowel disease and ankylosing spondylitis (INTEGRATE): a prospective and observational study protocol
Hyun Sik Kim, Bo-Hyung Kim, Bora Nam, Shin Ju Oh, Soo-Kyung Park, Sang Won Lee, Jae-Yun Lee, Sungsin Jo, Yeon-Ah Lee, June-Young Lee, Dong Il Park, Tae-Hwan Kim, Chang Kyun Lee
BMJ Open.2025; 15(8): e092075. CrossRef
Proteomic profiling of macrophages: effects of inflammatory activation and anti-inflammatory treatment with IBD therapeutics
Simone Lichtner, Kathrin Schunck, Johanna Frey, Janina Osti, Selina Dannheimer, Sabrina Schnur, Claus-Michael Lehr, Marc Schneider, Marius Hittinger
European Journal of Pharmaceutics and Biopharmaceutics.2025; 216: 114869. CrossRef
Elderly-onset inflammatory bowel disease in Asia: clinical characteristics and therapeutic strategies
Jiyoung Yoon, Daein Kim, You Sun Kim
Intestinal Research.2025; 23(4): 430. CrossRef
Editorial: Another brick in the CDST wall: Authors' reply
Kyuwon Kim, Byong Duk Ye
Alimentary Pharmacology & Therapeutics.2024; 60(1): 87. CrossRef
Cytokine Profile in Predicting the Effectiveness of Advanced Therapy for Ulcerative Colitis: A Narrative Review
Hiroki Kurumi, Yoshihiro Yokoyama, Takehiro Hirano, Kotaro Akita, Yuki Hayashi, Tomoe Kazama, Hajime Isomoto, Hiroshi Nakase
Biomedicines.2024; 12(5): 952. CrossRef
Revolutionizing Gastrointestinal Disorder Management: Cutting-Edge Advances and Future Prospects
Chahat Suri, Babita Pande, Tarun Sahu, Lakkakula Suhasini Sahithi, Henu Kumar Verma
Journal of Clinical Medicine.2024; 13(13): 3977. CrossRef

9,205 View
342 Download
10 Web of Science
12 Crossref

Original Article

IBD

Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy: Danny Con, Bridgette Andrew, Steven Nicolaides, Daniel R van Langenberg, Abhinav Vasudevan; Intest Res 2022;20(1):101-113. Published online March 12, 2021; DOI: https://doi.org/10.5217/ir.2020.00146

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
The residual risk of colectomy after infliximab salvage in steroid-refractory acute severe ulcerative colitis (ASUC) is required to inform the need for subsequent maintenance biologic therapy. The aim of this study was to determine the dynamic response of common serum biomarkers to infliximab salvage and assess their utility in predicting subsequent colectomy.
Methods
A retrospective single-center cohort study was conducted on all patients who received infliximab salvage for steroid-refractory ASUC between January 1, 2010, and July 31, 2019. Biomarkers were assessed on admission and days 1 and 3 post infliximab, and included C-reactive protein (CRP)-albumin-ratio (CAR), CRP-lymphocyte-ratio (CLR), platelet-lymphocyte-ratio (PLR) and neutrophil-lymphocyte-ratio (NLR).
Results
Of 94 patients (median age, 35 years; 67% of male), 20% required colectomy at 12 months. Biomarkers on day 3 post-infliximab best differentiated nonresponders, who had higher CRP, lower albumin and lower lymphocyte count (each P< 0.05). Day 3 predictive performance (area under the curve) for 12-month colectomy was best for CAR (0.871) and CLR (0.874), which were similar to Lindgren (0.829; P> 0.05) but superior to Mayo (0.726), partial Mayo (0.719), PLR (0.719), Ho index (0.714), NLR (0.675), Travis score (0.657) and endoscopic Mayo (0.609) (each P< 0.05). A day 3 CAR cutoff of 0.47 mg/g had 79% sensitivity, 80% specificity, 94% negative predictive value (NPV) to predict colectomy; while a day 3 CLR cutoff of 6.0 mg/10⁹ had 84% sensitivity, 84% specificity, 96% NPV.
Conclusions
CAR and CLR measured on day 3 post infliximab salvage for steroid-refractory ASUC represent simple and routinely performed biomarkers that appear to be strong predictors of colectomy. Prospective studies are required to confirm the utility of these predictive scores.

Citations

Citations to this article as recorded by

Endoscopic severity and C-reactive protein predict initial and 12-month outcomes of second-line medical therapy in acute severe ulcerative colitis: the RESCUE-ASC study
Pradeep Kakkadasam Ramaswamy, Deloshaan Subhaharan, Thomas Chapman, John Edwards, Lauren White, Desmond Patrick, Asif Shahzad, Laura Willmann, Dheeraj Shukla, Naveed Ishaq, Maneesha Bhullar, Alexander Dorrington, Jack Satsangi, Waled Mohsen
Frontline Gastroenterology.2025; : flgastro-2025-103253. CrossRef
Scoring indices for assessing endoscopic disease activity in acute severe ulcerative colitis: a systematic review
Hadar Meringer, Maia Kayal, Vipul Jairath, Anila Qasim, John K Macdonald, Yuhong Yuan, Christopher Ma, Jean-Frederic Colombel
Journal of Crohn’s and Colitis.2025;[Epub] CrossRef
Preoperative C-reactive protein-to-albumin ratio for perioperative risk stratification in penetrating crohn’s disease: identification of a candidate rule-out threshold (a propensity score-matched cohort study)
Kinuko Nagayoshi, Yusuke Mizuuchi, Takaaki Fujimoto, Koji Tamura, Kohei Nakata, Kenoki Ohuchida, Masafumi Nakamura
Surgery Today.2025;[Epub] CrossRef
Serum Procalcitonin Values Relate to Disease Activity in Patients with Inflammatory Bowel Diseases
İrfan Küçük, Süleyman Baş
Konuralp Tip Dergisi.2025; 17(1): 60. CrossRef
In Acute Severe Ulcerative Colitis Patients Who Receive Rescue Therapy, Prior Maintenance Therapy and Day 3 C-Reactive Protein After Rescue Therapy Are Associated With 12-Month Colectomy Risk
Jared A Sninsky, Ana-Maria Staicu, Edward L Barnes
Inflammatory Bowel Diseases.2024; 30(10): 1911. CrossRef
Factors Associated With Response to Rescue Therapy in Acute Severe Ulcerative Colitis
Christopher F D Li Wai Suen, Dean Seah, Matthew C Choy, Peter De Cruz
Inflammatory Bowel Diseases.2024; 30(8): 1389. CrossRef
Unresolved challenges in acute severe ulcerative colitis
Sudheer K. Vuyyuru, Vipul Jairath
Indian Journal of Gastroenterology.2024; 43(1): 9. CrossRef
Ischemia-modified albumin: a novel blood marker of endoscopic mucosal healing in inflammatory bowel disease
Seung Bum Lee, Hyun-Ki Kim, Sang Hyuk Park, Ji-Hun Lim, Sang Hyoung Park
Intestinal Research.2024; 22(1): 75. CrossRef
Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria
Makoto Naganuma, Naohiro Nakamura, Reiko Kunisaki, Katsuyoshi Matsuoka, Shojiro Yamamoto, Ami Kawamoto, Daisuke Saito, Taku Kobayashi, Kosaku Nanki, Kazuyuki Narimatsu, Hisashi Shiga, Motohiro Esaki, Shinichiro Yoshioka, Shingo Kato, Masayuki Saruta, Shin
Journal of Gastroenterology.2024; 59(4): 302. CrossRef
Which biomarkers best reflect the degree of inflammation in Crohn’s disease?
Jihye Park
Intestinal Research.2024; 22(1): 1. CrossRef
Acute severe ulcerative colitis management: unanswered questions and latest insights
Pauline Rivière, Christopher Li Wai Suen, María Chaparro, Peter De Cruz, Antonino Spinelli, David Laharie
The Lancet Gastroenterology & Hepatology.2024; 9(3): 251. CrossRef
Predictors of adverse outcomes of steroids in patients with severe ulcerative colitis (systematic review and meta-analyses)
A. F. Mingazov, O. I. Sushkov, B. R. Kalanov, T. A. Baranova, S. I. Achkasov
Koloproktologia.2024; 23(1): 172. CrossRef
Exploring the Role of GDF-15 in Inflammatory Bowel Disease: A Case-Controlled Study Comparing Crohn’s Disease and Ulcerative Colitis with Non-Inflammatory Controls
Ondřej Kučerka, Marie Blahutová, Vít Kosek, Petra Mináriková, Jan M. Horáček, Petr Urbánek, Martin Malý
Metabolites.2024; 14(4): 185. CrossRef
Clinical utility of C‐reactive protein‐to‐albumin ratio in the management of patients with inflammatory bowel disease
Anke L Nguyen, Claudia Brick, David Liu, David J Gibson, Peter R Gibson, Miles P Sparrow
JGH Open.2024;[Epub] CrossRef
Predicting Outcome after Acute Severe Ulcerative Colitis: A Contemporary Review and Areas for Future Research
Sudheer Kumar Vuyyuru, Olga Maria Nardone, Vipul Jairath
Journal of Clinical Medicine.2024; 13(15): 4509. CrossRef
Fecal, Blood, and Urinary Biomarkers in Inflammatory Bowel Diseases
Sarah Bencardino, Ferdinando D’Amico, Alessandra Zilli, Tommaso Lorenzo Parigi, Mariangela Allocca, Gionata Fiorino, Silvio Danese, Federica Furfaro
Journal of Translational Gastroenterology.2024; 2(2): 61. CrossRef
C-reactive protein-to-lymphocyte ratio is a novel biomarker for predicting the long-term efficacy of ustekinumab treatment in ulcerative colitis
Ryoji Koshiba, Kazuki Kakimoto, Noboru Mizuta, Keijiro Numa, Naohiko Kinoshita, Kei Nakazawa, Yuki Hirata, Takako Miyazaki, Kazuhide Higuchi, Shiro Nakamura, Hiroki Nishikawa, Senthilnathan Palaniyandi
PLOS ONE.2024; 19(8): e0305324. CrossRef
Defining management strategies for acute severe ulcerative colitis using predictive models: a simulation-modeling study
Danny Con, Peter De Cruz
Intestinal Research.2024; 22(4): 439. CrossRef
Predictors for colectomy in patients with acute severe ulcerative colitis: a systematic review and meta-analysis
Jieqi Zheng, Zinan Fan, Chao Li, Daiyue Wang, Shenghong Zhang, Rirong Chen
BMJ Open Gastroenterology.2024; 11(1): e001587. CrossRef
Can Inflammatory Indexes Predict the Severity of Mucosal Inflammation in Ulcerative Colitis?
İrfan Küçük, Ersin Tural
Duzce Medical Journal.2024; 26(3): 191. CrossRef
Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease
Marco Valvano, Annalisa Capannolo, Nicola Cesaro, Gianpiero Stefanelli, Stefano Fabiani, Sara Frassino, Sabrina Monaco, Marco Magistroni, Angelo Viscido, Giovanni Latella
Nutrients.2023; 15(17): 3824. CrossRef
Systematic review: Scores used to predict outcomes in acute severe ulcerative colitis
Maia Kayal, Hadar Meringer, Lily Martin, Jean Frederic Colombel
Alimentary Pharmacology & Therapeutics.2023; 58(10): 974. CrossRef
Clinical significance of the C-reactive protein-to-bilirubin ratio in patients with ulcerative colitis
Xijing Huang, Ya Liu, Zhou Zhou, Yan Pan, Yinghui Zhang, Caiping Gao, Chong He
Frontiers in Medicine.2023;[Epub] CrossRef
Exploring the diagnostic and prognostic value of the C-reactive protein/lymphocyte ratio for dilated cardiomyopathy based on a real-world study
Bin Qi, Zhi-Jie Yang, Nan Huang, Wen-Bo Zheng, Chun Gui
Scientific Reports.2023;[Epub] CrossRef
Novel Utility of Leucine-Rich Alpha-2-Glycoprotein as a Biomarker in Ulcerative Colitis: A Predictor of Endoscopic Remission Independent of Symptoms
Tomoyuki Hayashi, Kazuya Kitamura, Masaaki Usami, Masaki Miyazawa, Masaki Nishitani, Akihiro Dejima, Makoto Yamamoto, Shotaro Kawase, Masaya Funaki, Noriaki Orita, Hidetoshi Nakagawa, Koki Morita, Noriho Iida, Akihiro Seki, Kouki Nio, Hidenori Kido, Hideo
Inflammatory Intestinal Diseases.2023; 8(4): 133. CrossRef
Current and emerging biomarkers for ulcerative colitis
Jan K. Nowak, Rahul Kalla, Jack Satsangi
Expert Review of Molecular Diagnostics.2023; 23(12): 1107. CrossRef
Effect of disease duration on the association between C-reactive protein-albumin ratio and endoscopic activity in ulcerative colitis
Shinya Furukawa, Sen Yagi, Kana Shiraishi, Teruki Miyake, Kazuhiro Tange, Yu Hashimoto, Shogo Kitahata, Tomoe Kawamura, Tomoyuki Ninomiya, Kenichirou Mori, Seiyuu Suzuki, Naozumi Shibata, Hidehiro Murakami, Katsuhisa Ohashi, Aki Hasebe, Hideomi Tomida, Ya
BMC Gastroenterology.2022;[Epub] CrossRef
Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study
Hanyang Lin, Zhaohui Bai, Qiong Wu, Guiyang Chu, Yongguo Zhang, Xiaozhong Guo, Xingshun Qi
Frontiers in Public Health.2022;[Epub] CrossRef
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Ki
Intestinal Research.2022; 20(3): 350. CrossRef
Does C-reactive protein to serum Albumin Ratio correlate with diabEtic nephropathy in patients with Type 2 dIabetes MEllitus? The CARE TIME study
Satilmis Bilgin, Ozge Kurtkulagi, Burcin Meryem Atak Tel, Tuba Taslamacioglu Duman, Gizem Kahveci, Atiqa Khalid, Gulali Aktas
Primary Care Diabetes.2021; 15(6): 1071. CrossRef
Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review
Blake O. Langley, Sara E. Guedry, Joshua Z. Goldenberg, Douglas A. Hanes, Jennifer A. Beardsley, Jennifer Joan Ryan
Journal of Clinical Medicine.2021; 10(18): 4219. CrossRef

12,294 View
368 Download
33 Web of Science
31 Crossref

First
Prev
Page of 1
Next
Last

Search